Biotech stocks to watch in 2020
Whether a day trader or a long-term investor, we often examine research released by industry...
Whether a day trader or a long-term investor, we often examine research released by industry...
We maintain our Buy rating and are increasing our price target to A$0.16from A$0.09. The...
Prescient Therapeutics (PTX) shares rose 60 per cent this morning after expanding its Phase 1b...
Cancer drug developer Prescient Therapeutics (ASX: PTX) is expanding its Phase 1b study in patients with acute...
This week we were joined in office by Prescient Therapeutics (ASX: PTX) CEO and Managing...
Humankind has been trying to find a cure for cancer for thousands of years. Today,...
Prescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company which is engaged in small molecule drug...
Oncology company Prescient Therapeutics (ASX: PTX) has unveiled a potentially lucrative collaboration with Adelaide-based Carina Biotech to...
Prescient Therapeutics has entered a collaboration with Carina Biotech to develop new targeted cell therapies...
Stockhead’s resident Health and Biotech expert Tim Boreham is coming to you live from the 2019...

This investor centre was built by Reach Markets
©2025 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.